Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product NRx Pharmaceuticals wins FDA approval for ketamine, but NRXP stock falls. Explore its commercial plans, manufacturing strategy and outlook. bySoujanya RaviNovember 1, 2026